| Year |
Citation |
Score |
| 2020 |
Elkrief A, Desilets A, Papneja N, Cvetkovic L, Groleau C, Lakehal YA, Shbat L, Richard C, Malo J, Belkaid W, Cook E, Doucet S, Tran TH, Jao K, Daaboul N, ... ... Batist G, et al. High mortality among hospital-acquired COVID-19 infection in patients with cancer: A multicentre observational cohort study. European Journal of Cancer (Oxford, England : 1990). 139: 181-187. PMID 33035991 DOI: 10.1016/J.Ejca.2020.08.017 |
0.354 |
|
| 2020 |
Al-Thawadi H, Gupta I, Jabeen A, Skenderi F, Aboulkassim T, Yasmeen A, Malki MI, Batist G, Vranic S, Al Moustafa AE. Co-presence of human papillomaviruses and Epstein-Barr virus is linked with advanced tumor stage: a tissue microarray study in head and neck cancer patients. Cancer Cell International. 20: 361. PMID 32774155 DOI: 10.1186/S12935-020-01348-Y |
0.302 |
|
| 2020 |
Gniadek TJ, Augustin L, Schottel J, Leonard A, Saltzman D, Greeno E, Batist G. A Phase I, Dose Escalation, Single Dose Trial of Oral Attenuated Salmonella typhimurium Containing Human IL-2 in Patients With Metastatic Gastrointestinal Cancers. Journal of Immunotherapy (Hagerstown, Md. : 1997). PMID 32554977 DOI: 10.1097/Cji.0000000000000325 |
0.323 |
|
| 2020 |
Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, Shete S, Hsu CY, Desai A, de Lima Lopes G, Grivas P, Painter CA, Peters S, Thompson MA, Bakouny Z, ... Batist G, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet (London, England). PMID 32473681 DOI: 10.1016/S0140-6736(20)31187-9 |
0.354 |
|
| 2020 |
Wander SA, Cohen O, Gong X, Johnson GN, Buendia-Buendia JE, Lloyd MR, Kim D, Luo F, Mao P, Helvie K, Kowalski KJ, Nayar U, Waks AG, Parsons SH, Martinez R, ... ... Batist G, et al. The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor positive metastatic breast cancer. Cancer Discovery. PMID 32404308 DOI: 10.1158/2159-8290.Cd-19-1390 |
0.398 |
|
| 2020 |
Barrera I, Papneja N, Ranger J, Papneja A, Novotny P, Ahmed S, Batist G, Kavan P. First-line drug selection versus sequential treatment in advanced pancreatic cancer: Does it really matter? Multi-institutional Canadian perspective. Journal of Clinical Oncology. 38: 673-673. DOI: 10.1200/Jco.2020.38.4_Suppl.673 |
0.349 |
|
| 2020 |
Miller WH, Chu QS, Bouganim N, Jonker DJ, Batist G, Buhlaiga NJ, Lheureux S, Spratlin JL, Alcindor T, Smith PS, Owen J, Zaknoen SL, Stille JR, Fortier C, Vincett D, et al. A phase Ib study of oral Chk1 inhibitor LY2880070 as monotherapy in patients with advanced or metastatic cancer. Journal of Clinical Oncology. 38: 3579-3579. DOI: 10.1200/Jco.2020.38.15_Suppl.3579 |
0.308 |
|
| 2020 |
Ibrahim S, Sobsey CA, Popp R, Zahedi RP, Batist G, Borchers CH. Abstract P4-10-20: Protein quantitation assays for AKT and PTEN to better understand sensitivity and resistance of breast cancer patients to treatment with AKT inhibitor capivasertib Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P4-10-20 |
0.382 |
|
| 2020 |
Smyth LM, Batist G, Meric-Bernstam F, Kabos P, Spanggaard I, Lluch A, Schram A, Varga A, Wong A, Ambrose H, Barnicle A, Carr TH, Bruin ECd, Salinas-Souza C, Foxley A, et al. Abstract P1-19-05: Capivasertib (AZD5363) in combination with fulvestrant in PTEN-mutant ER+ metastatic breast cancer Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P1-19-05 |
0.378 |
|
| 2020 |
Marques M, Gambaro K, Tertre MCd, McNamara S, Hoffer C, Fajzel R, Batist G. Abstract 6494: Personalize My Treatment (PMT): A pan-Canadian initiative integrating precision oncology across Canada - PMT-001 pilot project Epidemiology. 80: 6494-6494. DOI: 10.1158/1538-7445.Am2020-6494 |
0.388 |
|
| 2020 |
Gambaro K, Marques M, McNamara S, Tertre MCd, Hoffert C, Srivastava A, Mathieu S, schab A, Alcindor T, Langleben A, Sideris L, Adbelsalam M, Tehfe M, Batist G, Kavan P. Abstract 4325: A Phase II exploratory study to identify biomarkers prognostic of clinical response to regorafenib in patients with metastatic colorectal cancer who have failed first-line therapy Endocrinology. DOI: 10.1158/1538-7445.Am2020-4325 |
0.352 |
|
| 2019 |
Gambaro K, Marques M, McNamara S, du Tertre MC, Hoffert C, Srivastava A, Samson B, Lesperance B, Ko Y, Dalfen R, St-Hilaire E, Sideris L, Couture F, Burkes R, Harb M, ... ... Batist G, et al. Copy number variation in longitudinal liver metastases biopsies in colorectal cancer identifies biomarker candidates of resistance to standard chemotherapy. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 30: iv133. PMID 32085039 DOI: 10.1093/Annonc/Mdz154.019 |
0.344 |
|
| 2019 |
Blank-Landeshammer B, Richard VR, Mitsa G, Marques M, LeBlanc A, Kollipara L, Feldmann I, Couetoux du Tertre M, Gambaro K, McNamara S, Spatz A, Zahedi RP, Sickmann A, Batist G, Borchers ACH. Proteogenomics of Colorectal Cancer Liver Metastases: Complementing Precision Oncology with Phenotypic Data. Cancers. 11. PMID 31805664 DOI: 10.3390/Cancers11121907 |
0.356 |
|
| 2019 |
Aguilar-Mahecha A, Joseph S, Cavallone L, Buchanan M, Krzemien U, Batist G, Basik M. Precision Medicine Tools to Guide Therapy and Monitor Response to Treatment in a HER-2+ Gastric Cancer Patient: Case Report. Frontiers in Oncology. 9: 698. PMID 31448226 DOI: 10.3389/Fonc.2019.00698 |
0.355 |
|
| 2019 |
Sinha S, Brown H, Tabak J, Fang Z, Tertre MCD, McNamara S, Gambaro K, Batist G, Buell JF. Multiplexed real-time polymerase chain reaction cell-free DNA assay as a potential method to monitor stage IV colorectal cancer. Surgery. PMID 31378479 DOI: 10.1016/J.Surg.2019.06.004 |
0.362 |
|
| 2019 |
Couetoux du Tertre M, Marques M, Tremblay L, Bouchard N, Diaconescu R, Blais N, Couture C, Pelsser V, Wang H, Higenell V, Izzi L, Gambaro K, Hoffert C, Srivastava A, Spatz A, ... ... Batist G, et al. Analysis of the genomic landscape in ALK+ NSCLC patients identifies novel aberrations associated with clinical outcomes. Molecular Cancer Therapeutics. PMID 31243098 DOI: 10.1158/1535-7163.Mct-19-0105 |
0.301 |
|
| 2019 |
Higenell V, Fajzel R, Batist G, Cheema PK, McArthur HL, Melosky B, Morris D, Petrella TM, Sangha R, Savard MF, Sridhar SS, Stagg J, Stewart DJ, Verma S. A network approach to developing immuno-oncology combinations in Canada. Current Oncology (Toronto, Ont.). 26: 73-79. PMID 31043804 DOI: 10.3747/Co.26.4393 |
0.308 |
|
| 2019 |
Rodon J, Soria JC, Berger R, Miller WH, Rubin E, Kugel A, Tsimberidou A, Saintigny P, Ackerstein A, Braña I, Loriot Y, Afshar M, Miller V, Wunder F, Bresson C, ... ... Batist G, et al. Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. Nature Medicine. PMID 31011205 DOI: 10.1038/S41591-019-0424-4 |
0.347 |
|
| 2019 |
Chu Q, Bouganim N, Fortier C, Zaknoen S, Stille JR, Kremer JD, Yuen E, Hui Y, Peña Adl, Lithio A, Smith PS, Batist G. Abstract CT083: A Phase I/II study of aurora kinase A inhibitor, LY3295668 erbumine (AK-01): Safety as monotherapy in patients with locally advanced or metastatic solid tumors Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct083 |
0.315 |
|
| 2019 |
Yuen E, Hui Y, Peña Adl, Tate SC, Stille JR, Lithio A, Smith PS, Chu Q, Batist G, Bouganim N, Fortier C, Zaknoen S, Kremer J. Abstract CT019: Population pharmacokinetics of an aurora kinase A inhibitor, LY3295668 erbumine (AK-01), in patients with locally advanced or metastatic solid tumors Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct019 |
0.319 |
|
| 2019 |
Papneja N, Ahmed S, Mondal P, Barrera I, Papneja A, Batist G, Kavan P. Outcomes of first-line FOLFIRINOX (FFX) versus gemcitabine and nab-paclitaxel (GN) in patients with advanced pancreatic cancer: Multi-Institutional Canadian sites experience Annals of Oncology. 30. DOI: 10.1093/Annonc/Mdz247.028 |
0.306 |
|
| 2018 |
Marques M, Gambaro K, du Tertre MC, Witcher M, Samson B, Lesperance B, Ko Y, Dalfen R, St-Hilaire E, Sideris L, Couture F, Tejpar S, Burkes R, Harb M, Alcindor T, ... ... Batist G, et al. Characterizations of DNA copy number variations and spatio-temporal intra tumor heterogeneity in liver metastasis from colorectal cancer patients. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: v93-v94. PMID 32177320 DOI: 10.1093/Annonc/Mdy150.005 |
0.34 |
|
| 2018 |
Batist G, Michaud S, Richards DP, Servidio-Italiano F, Stein BD. Developing a model of a patient-group pathway to accessing cancer clinical trials in Canada. Current Oncology (Toronto, Ont.). 25: e597-e609. PMID 30607129 DOI: 10.3747/Co.25.4213 |
0.327 |
|
| 2018 |
Alcaide M, Cheung M, Bushell K, Arthur SE, Wong HL, Karasinska J, Renouf D, Schaeffer DF, McNamara S, Tertre MCD, Batist G, Kennecke HF, Karsan A, Morin RD. A Novel Multiplex droplet digital PCR Assay to Identify and Quantify KRAS Mutations in Clinical Specimens. The Journal of Molecular Diagnostics : Jmd. PMID 30472330 DOI: 10.1016/J.Jmoldx.2018.09.007 |
0.35 |
|
| 2018 |
Mnatsakanyan R, Shema G, Basik M, Batist G, Borchers CH, Sickmann A, Zahedi RP. Detecting post-translational modification signatures as potential biomarkers in clinical mass spectrometry. Expert Review of Proteomics. PMID 29893147 DOI: 10.1080/14789450.2018.1483340 |
0.313 |
|
| 2018 |
Alahmad YM, Aljaber M, Saleh AI, Yalcin HC, Aboulkassim T, Yasmeen A, Batist G, Moustafa AA. Effect of cell-phone radiofrequency on angiogenesis and cell invasion in human head and neck cancer cells. Head & Neck. PMID 29756334 DOI: 10.1002/Hed.25210 |
0.352 |
|
| 2018 |
Saleh AI, Mohamed I, Mohamed AA, Abdelkader M, Yalcin HC, Aboulkassim T, Batist G, Yasmeen A, Moustafa AA. Elaeagnus angustifolia Plant Extract Inhibits Angiogenesis and Downgrades Cell Invasion of Human Oral Cancer Cells via Erk1/Erk2 Inactivation. Nutrition and Cancer. 1-9. PMID 29300111 DOI: 10.1080/01635581.2018.1412472 |
0.344 |
|
| 2018 |
Barrera I, Hamalova S, Ranger J, Rho H, Mamo A, Batist G, Kavan P. Folfirinox (FFX) versus gemcitabine with nab‐paclitaxel (GNP) in the first line treatment (1LTx) of metastatic pancreatic cancer (mPC): A tertiary center experience. Journal of Clinical Oncology. 36: 414-414. DOI: 10.1200/Jco.2018.36.4_Suppl.414 |
0.311 |
|
| 2018 |
Couetoux du Tertre M, Marques M, Tremblay L, Bouchard N, Diaconescu R, Blais N, Hoffert C, Srivastava A, Izzi L, McNamara S, Batist G, Cohen V, Agulnik JS. Molecular predictors of long-term response to crizotinib in ALK+ advanced non-small cell lung cancer (NSCLC) patients. Journal of Clinical Oncology. 36: e21038-e21038. DOI: 10.1200/Jco.2018.36.15_Suppl.E21038 |
0.328 |
|
| 2018 |
Tertre MCd, Marques M, Gambaro K, Witcher M, Samson B, Lespérance B, Ko Y, Dalfen R, St-Hilaire E, Sidéris L, Couture F, Tejpar S, Burkes R, Harb M, Camlioglu E, ... ... Batist G, et al. Abstract LB-231: Genomic profiling in serial metastatic colorectal tumors identifies copy number alterations and spatio temporal intra-patient heterogeneity profiles associated with clinical response. Q-CROC-01: NCT00984048 Cancer Research. 78. DOI: 10.1158/1538-7445.Am2018-Lb-231 |
0.387 |
|
| 2018 |
Popp R, Zahedi RP, LeBlanc A, Mohammed Y, Aguilar-Mahecha A, Pötz O, Basik M, Batist G, Borchers CH. Abstract LB-177: Quantification of cell signaling proteins by immuno-MALDI Cancer Research. 78. DOI: 10.1158/1538-7445.Am2018-Lb-177 |
0.4 |
|
| 2018 |
Sinha SK, Brown H, Fang Z, Couetoux M, Gambaro K, Batist G. Abstract 5575: A multiplexed RE-qPCR cell-free DNA assay to assess response and resistance to cancer therapy Cancer Research. 78: 5575-5575. DOI: 10.1158/1538-7445.Am2018-5575 |
0.365 |
|
| 2018 |
Buchanan M, Chabot C, Lafleur J, Krzemien U, Lan C, Savichtcheva O, Boileau J, Ferrario C, Savage P, Park M, Batist G, Aguilar-Mahecha A, Basik M. Abstract 2149: Use of PDXs and patient-derived cell lines to uncover unconventional drug therapies and combinations for the treatment of drug-resistant cancers Cancer Research. 78: 2149-2149. DOI: 10.1158/1538-7445.Am2018-2149 |
0.404 |
|
| 2017 |
Kasymjanova G, Small D, Cohen V, Jagoe RT, Batist G, Sateren W, Ernst P, Pepe C, Sakr L, Agulnik J. Lung cancer care trajectory at a Canadian centre: an evaluation of how wait times affect clinical outcomes. Current Oncology (Toronto, Ont.). 24: 302-309. PMID 29089797 DOI: 10.3747/Co.24.3611 |
0.307 |
|
| 2017 |
Banerji U, Dean E, Pérez-Fidalgo JA, Batist G, Bedard PL, You B, Westin SN, Kabos P, Garrett MD, Tall M, Ambrose HJ, Barrett JC, Carr TH, Cheung SA, Corcoran C, et al. A Phase 1 open-label study to identify a dosing regimen of the pan-AKT inhibitor AZD5363 for evaluation in solid tumors and in PIK3CA-mutated breast and gynecologic cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29066505 DOI: 10.1158/1078-0432.Ccr-17-2260 |
0.335 |
|
| 2017 |
Popp R, Li H, LeBlanc A, Mohammed Y, Aguilar-Mahecha A, Chambers AG, Lan C, Poetz O, Basik M, Batist G, Borchers CH. Immuno-MALDI (iMALDI) for quantifying AKT1 and AKT2 in breast and colorectal cancer cell lines and tumors. Analytical Chemistry. PMID 28853539 DOI: 10.1021/Acs.Analchem.7B02934 |
0.361 |
|
| 2017 |
Aguilar-Mahecha A, Lafleur J, Pelmus M, Seguin C, Lan C, Discepola F, Kovacina B, Christodoulopoulos R, Salvucci O, Mihalcioiu C, Roy JA, Robidoux A, Marcus EA, Batist G, Basik M. The identification of challenges in tissue collection for biomarker studies: the Q-CROC-03 neoadjuvant breast cancer translational trial experience. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. PMID 28752846 DOI: 10.1038/Modpathol.2017.82 |
0.344 |
|
| 2017 |
Suss S, Bhuiyan N, Demirli K, Batist G. Toward Implementing Patient Flow in a Cancer Treatment Center to Reduce Patient Waiting Time and Improve Efficiency. Journal of Oncology Practice. JOP2016020008. PMID 28471694 DOI: 10.1200/Jop.2016.020008 |
0.318 |
|
| 2017 |
Rho YS, Gilabert M, Polom K, Aladashvili A, Kopeckova K, Megdanova V, Coleman N, Greally M, Marrelli D, Roviello F, McDermott R, Petrova V, Mihaylova Z, Bortlicek Z, Prausova J, ... Batist G, et al. Comparing Clinical Characteristics and Outcomes of Young-onset and Late-onset Colorectal Cancer: An International Collaborative Study. Clinical Colorectal Cancer. PMID 28462853 DOI: 10.1016/J.Clcc.2017.03.008 |
0.316 |
|
| 2017 |
Gilabert M, Chanez B, Rho YS, Giovanini M, Turrini O, Batist G, Kavan P, Raoul JL. Evaluation of gemcitabine efficacy after the FOLFIRINOX regimen in patients with advanced pancreatic adenocarcinoma. Medicine. 96: e6544. PMID 28422841 DOI: 10.1097/Md.0000000000006544 |
0.31 |
|
| 2017 |
Barrera I, Filimon SD, Meng J, Kavan T, Rho Ys, Batist G, Kavan P. Gemcitabine plus nab-paclitaxel use in metastatic pancreatic cancer: A study of 40 patients. Journal of Clinical Oncology. 35: 498-498. DOI: 10.1200/Jco.2017.35.4_Suppl.498 |
0.319 |
|
| 2017 |
Soria J, Rodon Ahnert J, Berger R, Miller WH, Brana I, Loriot Y, Mughal TI, Lazar V, Wunder F, Bresson C, Koscielny S, Afshar M, Saintigny P, Tsimberidou AM, Richon C, ... Batist G, et al. WINTHER: An international study to select rational therapeutics based on the analysis of matched tumor and normal biopsies in subjects with advanced malignancies. Journal of Clinical Oncology. 35: TPS11625-TPS11625. DOI: 10.1200/Jco.2017.35.15_Suppl.Tps11625 |
0.359 |
|
| 2017 |
Couetoux du Tertre M, Tremblay L, Bouchard N, Diaconescu R, Blais N, Camlioglu E, Constantin A, Hoffert C, Gambaro K, Srivastava A, Greenwood C, Couture C, McNamara S, Batist G, Cohen V, et al. A phase IV study using multi-omics to identify mechanisms of response and resistance to crizotinib in ALK+ advanced non-small cell lung cancer (NSCLC) patients with distinct progression free survival outcomes. Journal of Clinical Oncology. 35: e20588-e20588. DOI: 10.1200/Jco.2017.35.15_Suppl.E20588 |
0.392 |
|
| 2017 |
Ferrario C, Laurin J, Kempen LV, Lambert C, Spatz A, Markova O, Batist G, Langleben A, Filion M, Jolivet J. Abstract CT098: Phase 1 first-in-human study of anti-clusterin antibody AB-16B5 in patients with advanced solid malignancies Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Ct098 |
0.349 |
|
| 2017 |
Gambaro K, Marques M, Morin R, Kleinman C, Witcher M, Turcotte S, Samson B, Lespérance B, Ko Y, Dalfen R, St-Hilaire E, Sideris L, Couture F, Tejpar S, Burkes R, ... ... Batist G, et al. Abstract 2795: Integrating multiomics discovery approaches to identify biomarkers of therapeutic resistance in metastatic colorectal cancer through analyses of multiple sequential tumor and liquid biopsies; Qcroc01: NCT00984048 Cancer Research. 77: 2795-2795. DOI: 10.1158/1538-7445.Am2017-2795 |
0.411 |
|
| 2016 |
D'Agostino NM, Pond GR, Aubin S, Matthew A, Gupta AA, Kavan P, Crump M, Bedard PL, Schuh AC, Hodgson DC, Wahl K, Simpson R, Vuong T, Muanza T, Batist G, et al. Neurocognitive function and psychological distress in young adults (YA) with cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 34: 199. PMID 28151359 DOI: 10.1200/Jco.2016.34.3_Suppl.199 |
0.302 |
|
| 2016 |
Mamo A, Easaw J, Ibnshamsah F, Baig A, Rho YS, Kavan T, Batist G, Kavan P. Retrospective analysis of the effect of CAPOX and mFOLFOX6 dose intensity on survival in colorectal patients in the adjuvant setting. Current Oncology (Toronto, Ont.). 23: 171-7. PMID 27330345 DOI: 10.3747/Co.23.3059 |
0.307 |
|
| 2016 |
Khare SR, Batist G, Bartlett G. Identification of performance indicators across a network of clinical cancer programs Current Oncology. 23: 81-90. DOI: 10.3747/Co.23.2789 |
0.356 |
|
| 2016 |
Rho Ys, Filimon SD, Barrera I, Azoulay L, McLean J, Kavan T, Mamo A, Batist G, Kavan P. More is not better. a time-dependent analysis of mortality in association with multiple treatments in the management of metastatic colorectal cancer. Journal of Clinical Oncology. 34. DOI: 10.1200/Jco.2016.34.15_Suppl.E15030 |
0.347 |
|
| 2015 |
McLean J, Rho YS, Kuruba G, Mamo A, Gilabert M, Kavan T, Panasci L, Melnychuk D, Batist G, Kavan P. Clinical Practice Patterns in Chemotherapeutic Treatment Regimens for Metastatic Colorectal Cancer. Clinical Colorectal Cancer. PMID 26553578 DOI: 10.1016/J.Clcc.2015.10.003 |
0.378 |
|
| 2015 |
Lazar V, Rubin E, Depil S, Pawitan Y, Martini JF, Gomez-Navarro J, Yver A, Kan Z, Dry JR, Kehren J, Validire P, Rodon J, Vielh P, Ducreux M, Galbraith S, ... ... Batist G, et al. A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer. Oncotarget. PMID 25944621 DOI: 10.18632/Oncotarget.3741 |
0.338 |
|
| 2015 |
Aboulkassim T, Yasmeen A, Akil N, Batist G, Al Moustafa AE. Incidence of Epstein-Barr virus in Syrian women with breast cancer: A tissue microarray study. Human Vaccines & Immunotherapeutics. 11: 951-5. PMID 25933186 DOI: 10.1080/21645515.2015.1009342 |
0.365 |
|
| 2015 |
Rodon J, Soria JC, Berger R, Batist G, Tsimberidou A, Bresson C, Lee JJ, Rubin E, Onn A, Schilsky RL, Miller WH, Eggermont AM, Mendelsohn J, Lazar V, Kurzrock R. Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. PMID 25908602 DOI: 10.1093/Annonc/Mdv191 |
0.353 |
|
| 2015 |
Edelstein K, D'Agostino NM, Pond GR, Aubin S, Matthew A, Wahl K, Gupta AA, Kavan P, Crump M, Bedard PL, Schuh AC, Hodgson DC, Vuong T, Muanza T, Batist G, et al. Cancer-related cognitive dysfunction (CRCD) and psychosocial development in young adult cancer survivors. Journal of Clinical Oncology. 33: TPS9636-TPS9636. DOI: 10.1200/Jco.2015.33.15_Suppl.Tps9636 |
0.356 |
|
| 2015 |
Mamo A, Baig A, Rho Ys, Kavan T, Easaw JC, Batist G, Kavan P. Impact of dose intensity of capox and mFOLFOX6 on survival of stage III colorectal cancer patients: A retrospective analysis at two Canadian institutions between 2006-2013. Journal of Clinical Oncology. 33. DOI: 10.1200/Jco.2015.33.15_Suppl.E14664 |
0.349 |
|
| 2015 |
Banerji U, Dean EJ, Perez-Fidalgo JA, Batist G, Bedard PL, You B, Westin SN, Kabos P, Davies B, Elvin P, Lawrence P, Yates JWT, Ambrose H, Rugman P, Foxley A, et al. A pharmacokinetically (PK) and pharmacodynamically (PD) driven phase I trial of the pan-AKT inhibitor AZD5363 with expansion cohorts in PIK3CA mutant breast and gynecological cancers. Journal of Clinical Oncology. 33: 2500-2500. DOI: 10.1200/Jco.2015.33.15_Suppl.2500 |
0.336 |
|
| 2015 |
McNamara S, Morin R, Tertre MCd, McCloskey R, Johnston R, Fornika D, Samson B, Lespérance B, Alcindor T, Ko Y, Dalfen R, St-Hilaire E, Sideris L, Couture F, Prenen H, ... ... Batist G, et al. Abstract 3888: Molecular profiling of sequential biopsies in patients with metastatic colorectal cancer identifies genomic alterations that evolve during first-line therapy and could have therapeutic implications: A prospective study to identify molecular mechanisms of clinical resistance (QCROC-01: NCT00984048). Cancer Research. 75: 3888-3888. DOI: 10.1158/1538-7445.Am2015-3888 |
0.413 |
|
| 2015 |
Gilabert M, Soo RY, Kavan T, Mamo A, Lean JM, Viens P, Raoul JL, Batist G, Kavan P. P-037Advanced Pancreatic Cancer Patients' Characteristics, Treatment and Outcome Based on Three Age Groups: ≤ 39, 39-74 and ≥ 75, a Report from Single Cancer Institution Annals of Oncology. 26. DOI: 10.1093/Annonc/Mdv233.37 |
0.339 |
|
| 2015 |
Schab A, Abdelsalam M, Aubin F, Langleben A, Couture F, Gologan A, Constantin A, Camlioglu E, Hoffert C, Batist G, Kavan P. P-306A phase II biopsy-driven study to identify biomarkers predictive of clinical response to second-line regorafenib in patients with metastatic colorectal cancer Annals of Oncology. 26. DOI: 10.1093/Annonc/Mdv233.303 |
0.33 |
|
| 2015 |
Gilabert M, Rho YS, Kavan T, Chanez B, Mamo A, Barrera I, McLean J, Viens P, Batist G, Kavan P. 2359 Optimal therapeutic sequences in the treatment of metastatic pancreatic cancer - a retrospective analysis from two Canadian and French tertiary cancer centres European Journal of Cancer. 51. DOI: 10.1016/S0959-8049(16)31275-8 |
0.349 |
|
| 2015 |
Mamo A, Rho YS, Gao YN, Kavan T, McLean J, Gilabert M, Ivan B, Batist G, Chaudhury P, Metrakos P, Panasci L, Kavan P. 2149 Impact of dose intensity in CAPOX and mFOLFOX6 in the treatment of metastatic colorectal cancer European Journal of Cancer. 51. DOI: 10.1016/S0959-8049(16)31070-X |
0.324 |
|
| 2014 |
Lorusso V, Śmiałowska-Janiszewska A, Krzemieniecki K, Novoa SA, Mefti F, Janssen J, Steger GG, Bird B, Turazza M, Yosef H, Albuisson E, Barnadas A, Batist G, De Mouzon J, Erdkamp F, et al. 396PUSE OF LIPOSOMAL DOXORUBICIN FOR METASTATIC BREAST CANCER MANAGEMENT ACROSS EUROPE: RESULTS OF EOS (EUROPEAN OBSERVATORY & SURVEY). Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv130-iv131. PMID 28170758 DOI: 10.1093/Annonc/Mdu329.45 |
0.321 |
|
| 2014 |
Ferrario C, Batist G. Advances in the approach to novel drug clinical development for breast cancer Expert Opinion On Drug Discovery. 9: 647-668. PMID 24758225 DOI: 10.1517/17460441.2014.911282 |
0.35 |
|
| 2014 |
Henriques L, Palumbo M, Guay MP, Bahoric B, Basik M, Kavan P, Batist G. Imiquimod in the treatment of breast cancer skin metastasis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: e22-5. PMID 24419128 DOI: 10.1200/Jco.2012.46.4883 |
0.318 |
|
| 2014 |
Chukkapalli S, Amessou M, Dekhil H, Dilly AK, Liu Q, Bandyopadhyay S, Thomas RD, Bejna A, Batist G, Kandouz M. Ehd3, a regulator of vesicular trafficking, is silenced in gliomas and functions as a tumor suppressor by controlling cell cycle arrest and apoptosis. Carcinogenesis. 35: 877-85. PMID 24306026 DOI: 10.1093/Carcin/Bgt399 |
0.38 |
|
| 2014 |
Chukkapalli S, Amessou M, Dilly AK, Dekhil H, Zhao J, Liu Q, Bejna A, Thomas RD, Bandyopadhyay S, Bismar TA, Neill D, Azoulay L, Batist G, Kandouz M. Role of the EphB2 receptor in autophagy, apoptosis and invasion in human breast cancer cells. Experimental Cell Research. 320: 233-46. PMID 24211352 DOI: 10.1016/J.Yexcr.2013.10.022 |
0.391 |
|
| 2014 |
Kavan P, Rousseau C, Aubin F, Langleben A, Gologan A, Zakarian R, Hoffert C, Batist G. Biopsy-driven study to identify biomarkers predictive of clinical response to second-line regorafenib in patients with metastatic colorectal cancer. Journal of Clinical Oncology. 32. DOI: 10.1200/Jco.2014.32.15_Suppl.Tps3656 |
0.359 |
|
| 2014 |
Mamo A, Kavan T, Rho YS, Batist G, Kavan P. Impact of dose intensity of XELOX and MFOLFOX6 on survival of metastatic colorectal cancer patients: A retrospective analysis at the Jewish General Hospital between 2006 and 2013. Journal of Clinical Oncology. 32. DOI: 10.1200/Jco.2014.32.15_Suppl.E14584 |
0.33 |
|
| 2014 |
Vuong T, Garant A, Niazi T, Kavan P, Vasilevsky CA, Letellier F, Boutros M, Batist G. PO-0703: Does neoadjuvant chemotherapy improve the pathologic complete remission rate for rectal cancer patients? Radiotherapy and Oncology. 111. DOI: 10.1016/S0167-8140(15)30821-5 |
0.346 |
|
| 2013 |
Butts C, Kamel-Reid S, Batist G, Chia S, Blanke C, Moore M, Sawyer MB, Desjardins C, Dubois A, Pun J, Bonter K, Ashbury FD. Benefits, issues, and recommendations for personalized medicine in oncology in Canada. Current Oncology (Toronto, Ont.). 20: e475-83. PMID 24155644 DOI: 10.3747/Co.20.1253 |
0.306 |
|
| 2013 |
Diaz Z, Aguilar-Mahecha A, Paquet ER, Basik M, Orain M, Camlioglu E, Constantin A, Benlimame N, Bachvarov D, Jannot G, Simard MJ, Chabot B, Gologan A, Klinck R, Gagnon-Kugler T, ... ... Batist G, et al. Next-generation biobanking of metastases to enable multidimensional molecular profiling in personalized medicine. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 26: 1413-24. PMID 23743930 DOI: 10.1038/Modpathol.2013.81 |
0.339 |
|
| 2013 |
Palumbo MO, Kavan P, Miller WH, Panasci L, Assouline S, Johnson N, Cohen V, Patenaude F, Pollak M, Jagoe RT, Batist G. Systemic cancer therapy: achievements and challenges that lie ahead. Frontiers in Pharmacology. 4: 57. PMID 23675348 DOI: 10.3389/Fphar.2013.00057 |
0.336 |
|
| 2013 |
Kandouz M, Zhao J, Bier A, Di Marco S, Oviedo-Landaverde I, Gallouzi IE, Batist G. Post-transcriptional regulation of connexin43 in H-Ras-transformed cells. Plos One. 8: e58500. PMID 23505521 DOI: 10.1371/Journal.Pone.0058500 |
0.311 |
|
| 2013 |
Gottlieb B, Alvarado C, Wang C, Gharizadeh B, Babrzadeh F, Richards B, Batist G, Basik M, Beitel LK, Trifiro M. Making sense of intratumor genetic heterogeneity: altered frequency of androgen receptor CAG repeat length variants in breast cancer tissues. Human Mutation. 34: 610-8. PMID 23377847 DOI: 10.1002/Humu.22287 |
0.35 |
|
| 2013 |
Wu JH, Batist G. Glutathione and glutathione analogues; therapeutic potentials. Biochimica Et Biophysica Acta. 1830: 3350-3. PMID 23201199 DOI: 10.1016/J.Bbagen.2012.11.016 |
0.34 |
|
| 2013 |
Puts MT, Monette J, Girre V, Wolfson C, Monette M, Batist G, Bergman H. The fall rate of older community-dwelling cancer patients. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer. 21: 775-83. PMID 22941117 DOI: 10.1007/S00520-012-1579-4 |
0.35 |
|
| 2013 |
Bouganim N, Mamo A, Wasserman DW, Batist G, Metrakos P, Chaudhury P, Hassanain M, Kavan P. Bevacizumab-based therapy for colorectal cancer: Experience from a large Canadian cohort at the Jewish General Hospital between 2004 and 2009 Current Oncology. 20: 247-251. DOI: 10.3747/Co.20.1370 |
0.31 |
|
| 2013 |
Mamo A, Cardoso Nogueira M, Batist G, Palumbo M, Panasci L, Ferrario C, Chaudhury P, Metrakos P, Kavan P. A real-life experience using panitumumab in chemo-refractory metastatic colorectal cancer patients: A retrospective analysis at the Jewish General Hospital, 2009-2012 Current Oncology. 20: e107-e112. DOI: 10.3747/Co.20.1271 |
0.354 |
|
| 2013 |
Gao YN, Mamo A, Palumbo MO, Batist G, Chaudhury P, Melnychuk D, Metrakos P, Panasci L, Kavan P. Are XELOX and FOLFOX equivalent in colorectal cancer? Dose intensity, toxicity, and treatment duration in clinical practice. Journal of Clinical Oncology. 31. DOI: 10.1200/Jco.2013.31.15_Suppl.E14556 |
0.308 |
|
| 2013 |
Langleben A, Supko JG, Hotte SJ, Batist G, Hirte HW, Rogoff H, Li Y, Li W, Kerstein D, Leggett D, Hitron MJ, Li C. A dose-escalation phase I study of a first-in-class cancer stemness inhibitor in patients with advanced malignancies. Journal of Clinical Oncology. 31: 2542-2542. DOI: 10.1200/Jco.2013.31.15_Suppl.2542 |
0.382 |
|
| 2013 |
Diaz Z, McNamara S, Holter S, Gallinger S, Batist G. The Canadian Colorectal Cancer Consortium: the First Large-Scale Molecular Based Approach to Translational Cancer Care in Canada Annals of Oncology. 24: iv37. DOI: 10.1093/Annonc/Mdt202.33 |
0.317 |
|
| 2013 |
Diaz Z, Przybytkowski E, Lan C, McNamara S, Aguilar-Mahecha A, Camlioglu E, Gologan A, Batist G, Basik M. MC13-0077 Array CGH analysis of paired metastatic biopsies obtained pre-treatment and at resistance to FOLFOX-bevacizumab in metastatic CRC patients European Journal of Cancer. 49. DOI: 10.1016/S0959-8049(13)70183-7 |
0.303 |
|
| 2012 |
Lafleur J, Ahmadzadeh E, Przybytkowski E, Seguin C, Mihalcioiu CL, Roy JA, Desbiens C, Robidoux A, Marcus EA, Diaz Z, Pelmus M, Batist G, Basik M. Biopsy-driven study to identify biomarkers of drug resistance in patients with triple-negative breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 87. PMID 28142495 DOI: 10.1200/Jco.2012.30.30_Suppl.87 |
0.404 |
|
| 2012 |
Sartore-Bianchi A, Delorenzi M, Gagnon-Kugler T, Rousseau C, Batist G. New frontiers in therapeutic resistance in cancer. Expert Review of Anticancer Therapy. 12: 877-9. PMID 22845402 DOI: 10.1586/Era.12.71 |
0.348 |
|
| 2012 |
Aguilar-Mahecha A, Lafleur J, Seguin C, Mihalcioiu CLD, Roy J, Desbiens C, Robidoux A, Diaz Z, Pelmus M, Batist G, Basik M. Q-CROC-03: A prospective biopsy driven clinical trial to study the mechanisms of resistance to chemotherapy in triple-negative breast cancer patients. Journal of Clinical Oncology. 30. DOI: 10.1200/Jco.2012.30.15_Suppl.Tps1139 |
0.395 |
|
| 2012 |
Batist G, Wu J, Abdulkassim T, Bendavit G, Abramovitz M. Abstract 820: Somatic mutations to identify tumors for highly selective chemosensitization by Nrf2 depletion Cancer Research. 72: 820-820. DOI: 10.1158/1538-7445.Am2012-820 |
0.392 |
|
| 2012 |
Diaz Z, Aguilar-Mahecha A, Basik M, Bachvarov D, Bélanger L, Benlimame N, Buchanan M, Camlioglu E, Chabot B, Constantin A, Courtemanche C, Gagnon-Kugler T, Gosselin L, McNamara S, Orain M, ... ... Batist G, et al. Abstract 3389: Determining optimal conditions for collection and processing of metastatic liver biopsies collected for a multicenter, prospective study to identify biomarkers of clinical resistance to first-line therapy in metastatic colorectal cancer Cancer Research. 72: 3389-3389. DOI: 10.1158/1538-7445.Am2012-3389 |
0.325 |
|
| 2012 |
Ferrario C, Miller WH, Charamis H, Langleben A, Oyewole-Eletu S, Dalfen R, Patenaude F, Batist G, Panasci LC. Abstract 2706: Phase 2 study with pharmacokinetics (PK) analysis of sorafenib and vinorelbine in metastatic breast cancer Cancer Research. 72: 2706-2706. DOI: 10.1158/1538-7445.Am2012-2706 |
0.361 |
|
| 2012 |
Aloyz R, Rousseau C, Diaz Z, Aguilar-Mahecha A, Basik M, Belanger L, Buchanan M, Camlioglu E, Constantin A, Benlimame N, McNamara S, Diaz Z, Orain M, Przybytkowski E, Spatz A, ... ... Batist G, et al. Abstract B24: De novo and acquired resistance to first-line standard therapy in colorectal cancer: from cell lines to metastatic tumors Clinical Cancer Research. 18: B24-B24. DOI: 10.1158/1078-0432.Mechres-B24 |
0.369 |
|
| 2012 |
Chan K, Vuong T, Kavan P, Niazi T, Holcroft C, Ferland E, Sturgeon J, Melnychuk D, Alcindor T, Batist G. Does the Compliance to Adjuvant Chemotherapy Depend on Neoadjuvant Radiation Therapy Modality Annals of Oncology. 23. DOI: 10.1016/S0923-7534(20)33198-7 |
0.317 |
|
| 2012 |
Aguilar-Mahecha A, Lafleur J, Seguin C, Rosenbloom M, Przybytkowski E, Pelmus M, Diaz Z, Batist G, Basik M. P3.02 Challenges in The Implementation of a Translational Research Biopsy-Driven Trial to Study Drug Resistance in Triple Negative Breast Cancer Patients Annals of Oncology. 23. DOI: 10.1016/S0923-7534(20)31355-7 |
0.374 |
|
| 2012 |
Vuong T, Niazi T, Devic S, Kavan P, Ferland E, Batist G. 267 Impact Of Timing Of Chemotherapy In The Treatment Of Patients With Operable Rectal Cancer: Preliminary Results From A Randomized Phase Ii Study Radiotherapy and Oncology. 102. DOI: 10.1016/S0167-8140(12)70232-3 |
0.328 |
|
| 2012 |
Vuong T, Niazi T, Paliga A, Coutlee F, Ferenczy A, Golagan A, Chong G, Steben M, Batist G. Targeted Treatment With Anti-EGFR Antibodies and Radiation Therapy for Patients With Squamous Cell Carcinoma of the Anal Canal: Rationale for a New Treatment Strategy International Journal of Radiation Oncology*Biology*Physics. 84: S697. DOI: 10.1016/J.Ijrobp.2012.07.1862 |
0.344 |
|
| 2011 |
Krzemieniecki K, Antolín Novoa S, Gozy M, Schumacher C, Steger GG, Carteni' G, Bird BR, Albuisson E, Barnadas A, Batist G, De Mouzon J, Erdkamp F, Leonard RC, Lueck H, Namer M, et al. Therapeutic management of metastatic breast cancer across Europe: European observatory and survey (EOS). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e11556. PMID 28021699 DOI: 10.1200/Jco.2011.29.15_Suppl.E11556 |
0.352 |
|
| 2011 |
Batist G, Wu JH, Spatz A, Miller WH, Cocolakis E, Rousseau C, Diaz Z, Ferrario C, Basik M. Resistance to cancer treatment: the role of somatic genetic events and the challenges for targeted therapies. Frontiers in Pharmacology. 2: 59. PMID 22007174 DOI: 10.3389/Fphar.2011.00059 |
0.371 |
|
| 2011 |
Verma S, McLeod D, Batist G, Robidoux A, Martins IR, Mackey JR. In the end what matters most? A review of clinical endpoints in advanced breast cancer. The Oncologist. 16: 25-35. PMID 21212428 DOI: 10.1634/Theoncologist.2010-0278 |
0.322 |
|
| 2011 |
Wan-Chow-Wah D, Monette J, Monette M, Sourial N, Retornaz F, Batist G, Puts MT, Bergman H. Difficulties in decision making regarding chemotherapy for older cancer patients: A census of cancer physicians. Critical Reviews in Oncology/Hematology. 78: 45-58. PMID 20335045 DOI: 10.1016/J.Critrevonc.2010.02.010 |
0.346 |
|
| 2011 |
Wasserman DW, Bouganim N, Batist G, Metrakos P, Chaudhury P, Hassanain M, Kavan P. Bevacizumab (Bev)-based therapy for patients (pts) with colorectal cancer (CRC): McGill University and Segal Cancer Centre experience. Journal of Clinical Oncology. 29: e14158-e14158. DOI: 10.1200/Jco.2011.29.15_Suppl.E14158 |
0.34 |
|
| 2011 |
Spatz A, Kempen LCv, Job B, Richon C, Barrois M, Dessen P, Lazar V, Michiels S, Helbling-Leclerc A, Dumay A, Petrella T, Batist G, Stas M, Schadendorf D, Oord Jvd, et al. Abstract 4835: Gonosome-linked expression of PPP2R3B in cutaneous melanoma correlates with distant metastasis free survival Cancer Research. 71: 4835-4835. DOI: 10.1158/1538-7445.Am2011-4835 |
0.305 |
|
| 2011 |
Puts MTE, Monette J, Girre V, Wolfson C, Monette M, Batist G, Bergman H. A pilot study on frailty, health and functioning in older newly-diagnosed cancer patients, what have we learned? Journal of Geriatric Oncology. 2: 233-238. DOI: 10.1016/J.Jgo.2011.04.002 |
0.365 |
|
| 2010 |
Aapro M, Bernard-Marty C, Brain EG, Batist G, Erdkamp F, Krzemieniecki K, Leonard R, Lluch A, Monfardini S, Ryberg M, Soubeyran P, Wedding U. Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 22: 257-67. PMID 20956616 DOI: 10.1093/Annonc/Mdq609 |
0.36 |
|
| 2010 |
Puts MT, Monette J, Girre V, Costa-Lima B, Wolfson C, Batist G, Bergman H. Potential medication problems in older newly diagnosed cancer patients in Canada during cancer treatment: a prospective pilot cohort study. Drugs & Aging. 27: 559-72. PMID 20583850 DOI: 10.2165/11537310-000000000-00000 |
0.341 |
|
| 2010 |
Kandouz M, Batist G. Gap junctions and connexins as therapeutic targets in cancer. Expert Opinion On Therapeutic Targets. 14: 681-92. PMID 20446866 DOI: 10.1517/14728222.2010.487866 |
0.365 |
|
| 2010 |
Puts MT, Monette J, Girre V, Wolfson C, Monette M, Batist G, Bergman H. Characteristics of older newly diagnosed cancer patients refusing cancer treatments. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer. 18: 969-74. PMID 20419496 DOI: 10.1007/S00520-010-0883-0 |
0.358 |
|
| 2010 |
Spatz A, Batist G, Eggermont AM. The biology behind prognostic factors of cutaneous melanoma. Current Opinion in Oncology. 22: 163-8. PMID 20177382 DOI: 10.1097/Cco.0B013E328337Fe8F |
0.312 |
|
| 2010 |
Kandouz M, Haidara K, Zhao J, Brisson ML, Batist G. The EphB2 tumor suppressor induces autophagic cell death via concomitant activation of the ERK1/2 and PI3K pathways Cell Cycle. 9: 398-407. PMID 20046096 DOI: 10.4161/Cc.9.2.10505 |
0.319 |
|
| 2010 |
Hu L, Miao W, Loignon M, Kandouz M, Batist G. Putative chemopreventive molecules can increase Nrf2-regulated cell defense in some human cancer cell lines, resulting in resistance to common cytotoxic therapies. Cancer Chemotherapy and Pharmacology. 66: 467-74. PMID 19940992 DOI: 10.1007/S00280-009-1182-7 |
0.439 |
|
| 2010 |
Puts MT, Monette J, Girre V, Wolfson C, Monette M, Batist G, Bergman H. Does frailty predict hospitalization, emergency department visits, and visits to the general practitioner in older newly-diagnosed cancer patients? Results of a prospective pilot study. Critical Reviews in Oncology/Hematology. 76: 142-51. PMID 19939699 DOI: 10.1016/J.Critrevonc.2009.10.006 |
0.302 |
|
| 2010 |
Loiselle CG, Edgar L, Batist G, Lu J, Lauzier S. The impact of a multimedia informational intervention on psychosocial adjustment among individuals with newly diagnosed breast or prostate cancer: a feasibility study. Patient Education and Counseling. 80: 48-55. PMID 19854604 DOI: 10.1016/J.Pec.2009.09.026 |
0.31 |
|
| 2010 |
Puts MT, Girre V, Monette J, Wolfson C, Monette M, Batist G, Bergman H. Clinical experience of cancer specialists and geriatricians involved in cancer care of older patients: A qualitative study. Critical Reviews in Oncology/Hematology. 74: 87-96. PMID 19427228 DOI: 10.1016/J.Critrevonc.2009.04.005 |
0.354 |
|
| 2009 |
Puts MT, Monette J, Girre V, Wolfson C, Monette M, Batist G, Bergman H. Participation of older newly-diagnosed cancer patients in an observational prospective pilot study: an example of recruitment and retention. Bmc Cancer. 9: 277. PMID 19664289 DOI: 10.1186/1471-2407-9-277 |
0.342 |
|
| 2009 |
Loignon M, Miao W, Hu L, Bier A, Bismar TA, Scrivens PJ, Mann K, Basik M, Bouchard A, Fiset PO, Batist Z, Batist G. Cul3 overexpression depletes Nrf2 in breast cancer and is associated with sensitivity to carcinogens, to oxidative stress, and to chemotherapy. Molecular Cancer Therapeutics. 8: 2432-40. PMID 19638449 DOI: 10.1158/1535-7163.Mct-08-1186 |
0.414 |
|
| 2009 |
Puts MT, Costa-Lima B, Monette J, Girre V, Wolfson C, Batist G, Bergman H. Medication problems in older, newly diagnosed cancer patients in Canada: How common are they? A prospective pilot study. Drugs & Aging. 26: 519-36. PMID 19591526 DOI: 10.2165/00002512-200926060-00008 |
0.351 |
|
| 2009 |
Theodoulou M, Batist G, Campos S, Winer E, Welles L, Hudis C. Phase I study of nonpegylated liposomal doxorubicin plus trastuzumab in patients with HER2-positive breast cancer. Clinical Breast Cancer. 9: 101-7. PMID 19433391 DOI: 10.3816/Cbc.2009.N.019 |
0.34 |
|
| 2009 |
Bier A, Oviedo-Landaverde I, Zhao J, Mamane Y, Kandouz M, Batist G. Connexin43 pseudogene in breast cancer cells offers a novel therapeutic target. Molecular Cancer Therapeutics. 8: 786-93. PMID 19372551 DOI: 10.1158/1535-7163.Mct-08-0930 |
0.417 |
|
| 2009 |
Zhou J, Geng G, Batist G, Wu JH. Syntheses and potential anti-prostate cancer activities of ionone-based chalcones. Bioorganic & Medicinal Chemistry Letters. 19: 1183-6. PMID 19138519 DOI: 10.1016/J.Bmcl.2008.12.089 |
0.306 |
|
| 2009 |
Bouganim N, Kavan P, Eid M, Metrakos P, Chaudhury P, Batist G. Perioperative chemotherapy with bevacizumab (BV) for liver metastases (LM) in colorectal cancer (CRC): McGill University pilot study Journal of Clinical Oncology. 27: e15027-e15027. DOI: 10.1200/Jco.2009.27.15_Suppl.E15027 |
0.303 |
|
| 2009 |
Puts MTE, Monette J, Girre V, Pepe C, Monette M, Assouline S, Panasci L, Basik M, Miller WH, Batist G, Wolfson C, Bergman H. P19 A novel way of assessing health and vulnerability in older newly-diagnosed cancer patients: results of a pilot study Critical Reviews in Oncology Hematology. 72. DOI: 10.1016/S1040-8428(09)70057-5 |
0.315 |
|
| 2008 |
Batist G, Sawyer M, Gabrail N, Christiansen N, Marshall JL, Spigel DR, Louie A. A multicenter, phase II study of CPX-1 liposome injection in patients (pts) with advanced colorectal cancer (CRC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 4108. PMID 27951075 DOI: 10.1200/Jco.2008.26.15_Suppl.4108 |
0.32 |
|
| 2008 |
Retornaz F, Monette J, Batist G, Monette M, Sourial N, Small D, Caplan S, Wan-Chow-Wah D, Puts MT, Bergman H. Usefulness of frailty markers in the assessment of the health and functional status of older cancer patients referred for chemotherapy: a pilot study. The Journals of Gerontology. Series a, Biological Sciences and Medical Sciences. 63: 518-22. PMID 18511757 DOI: 10.1093/Gerona/63.5.518 |
0.339 |
|
| 2008 |
Puts M, Monette J, Girre V, Pepe C, Monette M, Panasci L, Basik M, Batist G, Wolfson C, Bergman H. A novel way of assessing health and vulnerability in older newly diagnosed cancer patients: An ongoing prospective pilot study Journal of Clinical Oncology. 26: 20707-20707. DOI: 10.1200/Jco.2008.26.15_Suppl.20707 |
0.31 |
|
| 2008 |
Puts MTE, Monette J, Girre V, Pepe C, Monette M, Batist G, Wolfson C, Bergman H. Recruiting older newly-diagnosed cancer patients for an observational ongoing prospective cohort study: lessons learned Critical Reviews in Oncology Hematology. 68. DOI: 10.1016/S1040-8428(08)70065-9 |
0.308 |
|
| 2008 |
Wan-Chow-Wah D, Monette J, Monette M, Sourial N, Retornaz F, Batist G, Puts MTE, Bergman H. A census of cancer physicians in the province of Quebec: clinical experience with elderly patients Critical Reviews in Oncology Hematology. 68. DOI: 10.1016/S1040-8428(08)70056-8 |
0.329 |
|
| 2007 |
Batist G. Cardiac safety of liposomal anthracyclines. Cardiovascular Toxicology. 7: 72-4. PMID 17652807 DOI: 10.1007/S12012-007-0014-4 |
0.312 |
|
| 2007 |
Hamilton D, Wu JH, Batist G. Structure-based identification of novel human gamma-glutamylcysteine synthetase inhibitors. Molecular Pharmacology. 71: 1140-7. PMID 17229871 DOI: 10.1124/Mol.106.024778 |
0.3 |
|
| 2007 |
Retornaz FG, Monette J, Monette M, Sourial N, Wan-Chow-Wah D, Batist G, Bergman H. Usefulness of frailty markers in the assessment of the health and functional status in older cancer patient referred for chemotherapy Journal of Clinical Oncology. 25: 19673-19673. DOI: 10.1200/Jco.2007.25.18_Suppl.19673 |
0.351 |
|
| 2007 |
Kavan P, Melnychuk D, Langleben A, Baker SD, Bangash A, Gauthier C, Ranger M, Gourdeau H, Harvey MD, Falardeau P, Batist G. Phase I study of ECO-4601, a novel Ras pathway inhibitor Journal of Clinical Oncology. 25: 14128-14128. DOI: 10.1200/Jco.2007.25.18_Suppl.14128 |
0.325 |
|
| 2007 |
Puts MTE, Girre V, Monette J, Monette M, Wan-Chow-Wah D, Batist G, Wolfson C, Bergman H. P.32 Clinical experience of physicians involved in cancer treatment of older cancer patients: a qualitative interview study Critical Reviews in Oncology Hematology. 64. DOI: 10.1016/S1040-8428(13)70205-1 |
0.357 |
|
| 2007 |
Puts MTE, Monette J, Girre V, Pepe C, Monette M, Panasci L, Basik M, Miller W, Batist G, Wolfson C, Bergman H. A novel way of assessing health and vulnerability in older newly diagnosed cancer patients: preliminary results of an ongoing prospective pilot study. Critical Reviews in Oncology Hematology. 68. DOI: 10.1016/S1040-8428(08)70043-X |
0.324 |
|
| 2006 |
Cohen V, Agulnik JS, Jarry J, Batist G, Small D, Kreisman H, Tejada NA, Miller WH, Chong G. Evaluation of denaturing high-performance liquid chromatography as a rapid detection method for identification of epidermal growth factor receptor mutations in nonsmall-cell lung cancer. Cancer. 107: 2858-65. PMID 17096434 DOI: 10.1002/Cncr.22331 |
0.307 |
|
| 2006 |
Hernandez M, Shao Q, Yang XJ, Luh SP, Kandouz M, Batist G, Laird DW, Alaoui-Jamali MA. A histone deacetylation-dependent mechanism for transcriptional repression of the gap junction gene cx43 in prostate cancer cells. The Prostate. 66: 1151-61. PMID 16652385 DOI: 10.1002/Pros.20451 |
0.319 |
|
| 2006 |
Haïdara K, Zamir L, Shi QW, Batist G. The flavonoid Casticin has multiple mechanisms of tumor cytotoxicity action. Cancer Letters. 242: 180-90. PMID 16387422 DOI: 10.1016/J.Canlet.2005.11.017 |
0.389 |
|
| 2006 |
Batist G, Chi K, Miller W, Chia S, Hasanbasic F, Fisic A, Mayer L, Swenson C, Janoff A, Gelmon K. Phase 1 study of CPX-1, a fixed ratio formulation of irinotecan (IRI) and floxuridine (FLOX), in patients with advanced solid tumors Journal of Clinical Oncology. 24: 2014-2014. DOI: 10.1200/Jco.2006.24.18_Suppl.2014 |
0.335 |
|
| 2006 |
Miao W, Loignon M, Hu L, Basik M, Batist G. Cullin-3 is a potential novel target for breast cancer chemoprevention and treatment Journal of Clinical Oncology. 24: 13070-13070. DOI: 10.1200/Jco.2006.24.18_Suppl.13070 |
0.432 |
|
| 2006 |
Wan-Chow-Wah D, Retornaz F, Monette J, Monette M, Sourial N, Puts M, Batist G, Bergman H. 32 A census of cancer physicians in the province of Quebec: clinical experience with elderly patients Critical Reviews in Oncology Hematology. 60. DOI: 10.1016/S1040-8428(13)70103-3 |
0.329 |
|
| 2006 |
Retornaz F, Monette J, Monette M, Sourial N, Wan-Chow-Wah D, Puts M, Small D, Caplan S, Batist G, Bergman H. O9 Usefulness of frailty markers in the assessment of the health and functional status in older cancer patient referred for chemotherapy: a pilot study Critical Reviews in Oncology Hematology. 60. DOI: 10.1016/S1040-8428(13)70066-0 |
0.309 |
|
| 2005 |
Dent SF, Arnold A, Stewart DJ, Gertler S, Ayoub J, Batist G, Goss G, Nevile A, Soulieres D, Jolivet J, Mclntosh L, Seymour L. Phase II study of troxacitabine (BCH-4556) in patients with advanced non-small-cell lung cancer Lung. 183: 265-272. PMID 16211462 DOI: 10.1007/S00408-004-2539-7 |
0.346 |
|
| 2005 |
Chen EX, Batist G, Siu LL, Bangash N, Maclean M, McIntosh L, Miller WH, Oza AM, Lathia C, Petrenciuc O, Seymour L. Phase I and pharmacokinetic study of Bay 38-3441, a camptothecin glycoconjugate, administered as a 30-minute infusion daily for five days every 3 weeks in patients with advanced solid malignancies. Investigational New Drugs. 23: 455-65. PMID 16133797 DOI: 10.1007/S10637-005-2905-1 |
0.303 |
|
| 2005 |
Mackenzie MJ, Hirte HW, Glenwood G, Jean M, Goel R, Major PP, Miller WH, Panasci L, Lorimer IA, Batist G, Matthews S, Douglas L, Seymour L. A phase II trial of ZD1839 (Iressa) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer. Investigational New Drugs. 23: 165-70. PMID 15744593 DOI: 10.1007/S10637-005-5862-9 |
0.335 |
|
| 2005 |
Goss G, Hirte H, Miller WH, Lorimer IA, Stewart D, Batist G, Parolin DA, Hanna P, Stafford S, Friedmann J, Walsh W, Mathews S, Douglas L, Seymour LK. A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group. Investigational New Drugs. 23: 147-55. PMID 15744591 DOI: 10.1007/S10637-005-5860-Y |
0.31 |
|
| 2005 |
Lapointe R, Létourneau R, Steward W, Hawkins RE, Batist G, Vincent M, Whittom R, Eatock M, Jolivet J, Moore M. Phase II study of troxacitabine in chemotherapy-naïve patients with advanced cancer of the pancreas Annals of Oncology. 16: 289-293. PMID 15668286 DOI: 10.1093/Annonc/Mdi061 |
0.353 |
|
| 2005 |
Batist G. Surrogate Endpoints in Colorectal Cancer Current Oncology. 12. DOI: 10.3747/Co.V12I4.75 |
0.33 |
|
| 2004 |
Miao W, Hu L, Kandouz M, Hamilton D, Batist G. A cell-based system to identify and characterize the molecular mechanism of drug-metabolizing enzyme (DME) modulators. Biochemical Pharmacology. 67: 1897-905. PMID 15130766 DOI: 10.1016/J.Bcp.2004.02.009 |
0.335 |
|
| 2004 |
Kandouz M, Bier A, Carystinos GD, Alaoui-Jamali MA, Batist G. Connexin43 pseudogene is expressed in tumor cells and inhibits growth. Oncogene. 23: 4763-70. PMID 15122329 DOI: 10.1038/Sj.Onc.1207506 |
0.785 |
|
| 2004 |
Petrella M, Montaner J, Batist G, Wainberg MA. The role of surrogate markers in the clinical development of antiretroviral therapy: a model for early evaluation of targeted cancer drugs. Cancer Investigation. 22: 149-60. PMID 15069773 DOI: 10.1081/Cnv-120027590 |
0.304 |
|
| 2004 |
Hamilton D, Batist G. Glutathione analogues in cancer treatment. Current Oncology Reports. 6: 116-22. PMID 14751089 DOI: 10.1007/S11912-004-0023-4 |
0.416 |
|
| 2003 |
Latreille J, Batist G, Laberge F, Champagne P, Croteau D, Falardeau P, Levinton C, Hariton C, Evans WK, Dupont E. Phase I/II trial of the safety and efficacy of AE-941 (Neovastat) in the treatment of non-small-cell lung cancer. Clinical Lung Cancer. 4: 231-6. PMID 14624712 DOI: 10.3816/Clc.2003.N.003 |
0.364 |
|
| 2003 |
Carystinos GD, Kandouz M, Alaoui-Jamali MA, Batist G. Unexpected induction of the human connexin 43 promoter by the ras signaling pathway is mediated by a novel putative promoter sequence. Molecular Pharmacology. 63: 821-31. PMID 12644583 DOI: 10.1124/Mol.63.4.821 |
0.758 |
|
| 2002 |
Hamilton D, Fotouhi-Ardakani N, Batist G. The glutathione system in alkylator resistance. Cancer Treatment and Research. 112: 67-87. PMID 12481712 DOI: 10.1007/978-1-4615-1173-1_4 |
0.769 |
|
| 2002 |
Batist G, Barton J, Chaikin P, Swenson C, Welles L. Myocet (liposome-encapsulated doxorubicin citrate): a new approach in breast cancer therapy. Expert Opinion On Pharmacotherapy. 3: 1739-51. PMID 12472371 DOI: 10.1517/14656566.3.12.1739 |
0.355 |
|
| 2002 |
Seiden MV, Swenerton KD, Matulonis U, Campos S, Rose P, Batist G, Ette E, Garg V, Fuller A, Harding MW, Charpentier D. A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy. Gynecologic Oncology. 86: 302-10. PMID 12217752 DOI: 10.1006/Gyno.2002.6762 |
0.351 |
|
| 2002 |
Batist G, Patenaude F, Champagne P, Croteau D, Levinton C, Hariton C, Escudier B, Dupont E. Neovastat (AE-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 13: 1259-63. PMID 12181250 DOI: 10.1093/Annonc/Mdf195 |
0.352 |
|
| 2002 |
Al Moustafa AE, Alaoui-Jamali MA, Batist G, Hernandez-Perez M, Serruya C, Alpert L, Black MJ, Sladek R, Foulkes WD. Identification of genes associated with head and neck carcinogenesis by cDNA microarray comparison between matched primary normal epithelial and squamous carcinoma cells. Oncogene. 21: 2634-40. PMID 11965536 DOI: 10.1038/Sj.Onc.1205351 |
0.344 |
|
| 2002 |
Katabi M, Yuan S, Chan H, Galipeau J, Batist G. The nonapoptotic pathway mediating thymidine kinase/ganciclovir toxicity is reduced by signal from adenovirus type 5 early region 4. Molecular Therapy : the Journal of the American Society of Gene Therapy. 5: 170-6. PMID 11829524 DOI: 10.1006/Mthe.2002.0521 |
0.326 |
|
| 2001 |
Carystinos GD, Bier A, Batist G. The role of connexin-mediated cell-cell communication in breast cancer metastasis. Journal of Mammary Gland Biology and Neoplasia. 6: 431-40. PMID 12013532 DOI: 10.1023/A:1014787014851 |
0.786 |
|
| 2001 |
Trudeau C, Yuan S, Galipeau J, Benlimame N, Alaoui-Jamali MA, Batist G. A novel parasite-derived suicide gene for cancer gene therapy with specificity for lung cancer cells Human Gene Therapy. 12: 1673-1680. PMID 11535170 DOI: 10.1089/10430340152528165 |
0.386 |
|
| 2001 |
Carystinos GD, Alaoui-Jamali MA, Phipps J, Yen L, Batist G. Upregulation of gap junctional intercellular communication and connexin 43 expression by cyclic-AMP and all-trans-retinoic acid is associated with glutathione depletion and chemosensitivity in neuroblastoma cells Cancer Chemotherapy and Pharmacology. 47: 126-132. PMID 11269738 DOI: 10.1007/S002800000231 |
0.773 |
|
| 2001 |
Batist G, Ramakrishnan G, Rao CS, Chandrasekharan A, Gutheil J, Guthrie T, Shah P, Khojasteh A, Nair MK, Hoelzer K, Tkaczuk K, Youn Choi Park, Lee LW. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer Journal of Clinical Oncology. 19: 1444-1454. PMID 11230490 DOI: 10.1200/Jco.2001.19.5.1444 |
0.336 |
|
| 2001 |
Caruso JA, Reiners JJ, Emond J, Shultz T, Tainsky MA, Alaoui-Jamali M, Batist G. Genetic alteration of chromosome 8 is a common feature of human mammary epithelial cell lines transformed in vitro with benzo[a]pyrene. Mutation Research. 473: 85-99. PMID 11166028 DOI: 10.1016/S0027-5107(00)00140-8 |
0.316 |
|
| 2000 |
Jaitovitch-Groisman I, Fotouhi-Ardakani N, Schecter RL, Woo A, Alaoui-Jamali MA, Batist G. Modulation of glutathione S-transferase alpha by hepatitis B virus and the chemopreventive drug oltipraz Journal of Biological Chemistry. 275: 33395-33403. PMID 10934196 DOI: 10.1074/Jbc.M003754200 |
0.769 |
|
| 2000 |
Yen L, You XL, Al Moustafa AE, Batist G, Hynes NE, Mader S, Meloche S, Alaoui-Jamali MA. Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis Oncogene. 19: 3460-3469. PMID 10918604 DOI: 10.1038/Sj.Onc.1203685 |
0.345 |
|
| 2000 |
Sohn S, Jaitovitch-Groisman I, Benlimame N, Galipeau J, Batist G, Alaoui-Jamali MA. Retroviral expression of the hepatitis B virus x gene promotes liver cell susceptibility to carcinogen-induced site specific mutagenesis Mutation Research - Dna Repair. 460: 17-28. PMID 10856831 DOI: 10.1016/S0921-8777(00)00010-0 |
0.328 |
|
| 2000 |
Fotouhi-Ardakani N, Schecter RL, Batist G. Evidence for genomic duplication of the glutathione transferase A3 gene in genus Rattus. Molecular Biology and Evolution. 17: 331-5. PMID 10677856 DOI: 10.1093/Oxfordjournals.Molbev.A026313 |
0.739 |
|
| 1999 |
Cripps C, Burnell M, Jolivet J, Batist G, Lofters W, Dancey J, Iglesias J, Fisher B, Eisenhauer EA. Phase II study of first-line LY231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer: An NCIC Clinical Trials Group study Annals of Oncology. 10: 1175-1179. PMID 10586333 DOI: 10.1023/A:1008372529239 |
0.328 |
|
| 1999 |
Caruso JA, Laird DW, Batist G. Role of HSP90 in mediating cross-talk between the estrogen receptor and the Ah receptor signal transduction pathways. Biochemical Pharmacology. 58: 1395-403. PMID 10513983 DOI: 10.1016/S0006-2952(99)00225-7 |
0.324 |
|
| 1999 |
Gelmon K, Eisenhauer E, Bryce C, Tolcher A, Mayer L, Tomlinson E, Zee B, Blackstein M, Tomiak E, Yau J, Batist G, Fisher B, Iglesias J. Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer Journal of Clinical Oncology. 17: 3038-3047. PMID 10506598 DOI: 10.1200/Jco.1999.17.10.3038 |
0.325 |
|
| 1999 |
Laird DW, Fistouris P, Batist G, Alpert L, Huynh HT, Carystinos GD, Alaoui-Jamali MA. Deficiency of connexin43 gap junctions is an independent marker for breast tumors. Cancer Research. 59: 4104-10. PMID 10463615 |
0.786 |
|
| 1999 |
Caruso JA, Batist G. Divergent mechanisms for loss of Ah-responsiveness in benzo[a]pyrene- and adriamycinR-resistant MCF-7 cells. Biochemical Pharmacology. 57: 1253-63. PMID 10230769 DOI: 10.1016/S0006-2952(99)00041-6 |
0.372 |
|
| 1999 |
Fotouhi-Ardakani N, Batist G. Genomic cloning and characterization of the rat glutathione S-transferase-A3-subunit gene. The Biochemical Journal. 339: 685-93. PMID 10215608 DOI: 10.1042/Bj3390685 |
0.768 |
|
| 1999 |
Katabi MM, Chan HL, Karp SE, Batist G. Hexokinase type II: a novel tumor-specific promoter for gene-targeted therapy differentially expressed and regulated in human cancer cells. Human Gene Therapy. 10: 155-64. PMID 10022541 DOI: 10.1089/10430349950018959 |
0.394 |
|
| 1999 |
Carystinos GD, Katabi MM, Laird DW, Galipeau J, Chan H, Alaoui-Jamali MA, Batist G. Cyclic-AMP induction of gap junctional intercellular communication increases bystander effect in suicide gene therapy Clinical Cancer Research. 5: 61-68. PMID 9918203 |
0.769 |
|
| 1999 |
Cripps C, Batist G, Dahrouge S, Fry D, McQuillan A, Kolendowicz R, Abugaber AA. A Phase I study of ‘Tomudex’ and gemcitabine in advanced cancer European Journal of Cancer. 35. DOI: 10.1016/S0959-8049(99)81582-2 |
0.328 |
|
| 1999 |
Evans W, Latreille J, Batist G, Falardeau P, Champagne P, Rivière M, Dupont E. Æ-941, an inhibitor of angiogenesis: rationale for development in combination with induction chemotherapy/radiotherapy in patients with non-small-cell lung cancer (nsclc) European Journal of Cancer. 35: S250. DOI: 10.1016/S0959-8049(99)81412-9 |
0.343 |
|
| 1998 |
Lilenbaum RC, Miller AA, Batist G, Bernard S, Hollis DR, Rosner GL, Egorin MJ, Schilsky RL, Ratain MJ. Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: A cancer and leukemia group B study Journal of Clinical Oncology. 16: 3302-3309. PMID 9779705 DOI: 10.1200/Jco.1998.16.10.3302 |
0.33 |
|
| 1998 |
Chen X, Batist G. Sensitization effect of L-2-oxothiazolidine-4-carboxylate on tumor cells to melphalan and the role of 5-oxo-L-prolinase in glutathione modulation in tumor cells. Biochemical Pharmacology. 56: 743-9. PMID 9751079 DOI: 10.1016/S0006-2952(98)00223-8 |
0.378 |
|
| 1998 |
Chen X, Carystinos GD, Batist G. Potential for selective modulation of glutathione in cancer chemotherapy. Chemico-Biological Interactions. 111: 263-75. PMID 9679560 DOI: 10.1016/S0009-2797(97)00166-X |
0.783 |
|
| 1998 |
Fotouhi-Ardakani N, Woo A, Lewandowska M, Schecter R, Batist G. Identification of the Yc1 glutathione S-transferase mRNA as the overexpressed species in a nitrogen mustard-resistant rat mammary carcinoma cell line. Journal of Biochemical and Molecular Toxicology. 12: 11-7. PMID 9414483 DOI: 10.1002/(Sici)1099-0461(1998)12:1<11::Aid-Jbt3>3.0.Co;2-S |
0.783 |
|
| 1997 |
Swenerton K, Hoskins P, Stuart G, Batist G, Pike J, Onetto N, Fisher B, Eisenhauer E. A phase I study of bi-weekly paclitaxel/cisplatin as initial therapy for advanced ovarian cancer. A study of the National Cancer Institute of Canada Clinical Trials Group. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 7: 1077-9. PMID 9037368 DOI: 10.1093/Oxfordjournals.Annonc.A010502 |
0.349 |
|
| 1996 |
Kirby GM, Batist G, Fotouhi-Ardakani N, Nakazawa H, Yamasaki H, Kew M, Cameron RG, Alaoui-Jamali MA. Allele-specific PCR analysis of p53 codon 249 AGT transversion in liver tissues from patients with viral hepatitis International Journal of Cancer. 68: 21-25. PMID 8895534 DOI: 10.1002/(Sici)1097-0215(19960927)68:1<21::Aid-Ijc4>3.0.Co;2-Z |
0.757 |
|
| 1996 |
Panasci L, Jean-Claude BJ, Vasilescu D, Mustafa A, Damian S, Damian Z, Georges E, Liu Z, Batist G, Leyland-Jones B. Sensitization to doxorubicin resistance in breast cancer cell lines by tamoxifen and megestrol acetate. Biochemical Pharmacology. 52: 1097-102. PMID 8831729 DOI: 10.1016/0006-2952(96)00456-X |
0.376 |
|
| 1995 |
Trudeau M, Zukiwski A, Langleben A, Boos G, Batist G. A phase I study of recombinant human interferon alpha-2b combined with 5-fluorouracil and cisplatin in patients with advanced cancer. Cancer Chemotherapy and Pharmacology. 35: 496-500. PMID 7882458 DOI: 10.1007/Bf00686834 |
0.303 |
|
| 1995 |
Baruchel S, Wang T, Farah R, Jamali M, Batist G. In vivo selective modulation of tissue glutathione in a rat mammary carcinoma model. Biochemical Pharmacology. 50: 1505-8. PMID 7503802 DOI: 10.1016/0006-2952(95)02063-2 |
0.362 |
|
| 1995 |
Yen L, Woo A, Christopoulopoulos G, Batist G, Panasci L, Roy R, Mitra S, Alaoui-Jamali MA. Enhanced host cell reactivation capacity and expression of DNA repair genes in human breast cancer cells resistant to bi-functional alkylating agents Mutation Research-Dna Repair. 337: 179-189. PMID 7491121 DOI: 10.1016/0921-8777(95)00022-C |
0.375 |
|
| 1994 |
Alaoui-Jamali M, Loubaba BB, Robyn S, Tapiero H, Batist G. Effect of DNA-repair-enzyme modulators on cytotoxicity of L-phenylalanine mustard and cis-diamminedichloroplatinum (II) in mammary carcinoma cells resistant to alkylating drugs. Cancer Chemotherapy and Pharmacology. 34: 153-8. PMID 8194166 DOI: 10.1007/Bf00685933 |
0.315 |
|
| 1994 |
C.-Gaudreault R, Alaoui-Jamali MA, Batist G, Béchard P, Lacroix J, Poyet P. Lack of cross-resistance to a new cytotoxic arylchloroethyl urea in various drug-resistant tumor cells Cancer Chemotherapy and Pharmacology. 33: 489-492. PMID 8137459 DOI: 10.1007/Bf00686506 |
0.363 |
|
| 1994 |
Lehnert S, Vestergaard J, Batist G, Aloui-Jamali MA. Radiation Resistance in a Melphalan-Resistant Subline of a Rat Mammary Carcinoma Radiation Research. 139: 232. DOI: 10.2307/3578669 |
0.305 |
|
| 1992 |
Trudeau M, Batist G, Thirlwell M, Boos G, Shennib H, Mulder D. Neoadjuvant chemotherapy with cytosine arabinoside by continuous infusion and cisplatin for resectable squamous cell carcinoma of the esophagus. Journal of Surgical Oncology. 50: 118-20. PMID 1593882 DOI: 10.1002/Jso.2930500213 |
0.336 |
|
| 1992 |
Alaoui-Jamali MA, Panasci L, Centurioni GM, Schecter R, Lehnert S, Batist G. Nitrogen mustard-DNA interaction in melphalan-resistant mammary carcinoma cells with elevated intracellular glutathione and glutathione-S-transferase activity Cancer Chemotherapy and Pharmacology. 30: 341-347. PMID 1505071 DOI: 10.1007/Bf00689960 |
0.338 |
|
| 1992 |
Schecter RL, Alaoui-Jamali MA, Batist G. Glutathione S-transferase in chemotherapy resistance and in carcinogenesis Biochemistry and Cell Biology = Biochimie Et Biologie Cellulaire. 70: 349-353. PMID 1353967 DOI: 10.1139/O92-054 |
0.34 |
|
| 1991 |
Batist G, Schecter R, Woo A, Greene D, Lehnert S. Glutathione depletion in human and in rat multi-drug resistant breast cancer cell lines. Biochemical Pharmacology. 41: 631-5. PMID 1997009 DOI: 10.1016/0006-2952(91)90638-L |
0.396 |
|
| 1990 |
Dmitrovsky E, Seifter EJ, Gazdar AF, Tsai CM, Edison M, Brantley P, Veach SR, Batist G, Ihde DC, Mulshine JL. A phase II trial of carboplatin (CBDCA) in small-cell and non-small-cell lung cancer with correlation to in vitro analysis of cytotoxicity. American Journal of Clinical Oncology. 13: 285-9. PMID 2165737 DOI: 10.1097/00000421-199008000-00003 |
0.363 |
|
| 1990 |
Lehnert S, Greene D, Batist G. Radiation Response of Drug-Resistant Variants of a Human Breast Cancer Cell Line: The Effect of Glutathione Depletion Radiation Research. 124: 208. DOI: 10.2307/3577868 |
0.381 |
|
| 1989 |
Tsao MS, Duong M, Batist G. Glutathione and glutathione S-transferases in clones of cultured rat liver epithelial cells that express varying activity of γ-glutamyl transpeptidase Molecular Carcinogenesis. 2: 144-149. PMID 2477028 DOI: 10.1002/Mc.2940020307 |
0.33 |
|
| 1989 |
Lehnert S, Greene D, Batist G. Radiation Response of Drug-Resistant Variants of a Human Breast Cancer Cell Line Radiation Research. 118: 568. DOI: 10.2307/3577414 |
0.362 |
|
| 1987 |
Cowan KH, Batist G, Tulpule A, Sinha BK, Myers CE. Similar biochemical changes associated with multidrug resistance in human breast cancer cells and carcinogen-induced resistance to xenobiotics in rats. Proceedings of the National Academy of Sciences of the United States of America. 83: 9328-32. PMID 3540935 DOI: 10.1073/Pnas.83.24.9328 |
0.361 |
|
| 1987 |
Sinha BK, Katki AG, Batist G, Cowan KH, Myers CE. Differential formation of hydroxyl radicals by adriamycin in sensitive and resistant MCF-7 human breast tumor cells: implications for the mechanism of action. Biochemistry. 26: 3776-81. PMID 2820475 DOI: 10.1021/Bi00387A006 |
0.345 |
|
| 1986 |
Batist G, Behrens BC, Makuch R, Hamilton TC, Katki AG, Louie KG, Myers CE, Ozols RF. Serial determinations of glutathione levels and glutathione-related enzyme activities in human tumor cells in vitro. Biochemical Pharmacology. 35: 2257-9. PMID 3827990 DOI: 10.1016/0006-2952(86)90601-5 |
0.305 |
|
| 1986 |
Batist G, Carney DN, Cowan KH, Veach SR, Gilliom M, Bunn PA, Ihde DC. Etoposide (VP-16) and cisplatin in previously treated small-cell lung cancer: clinical trial and in vitro correlates. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 4: 982-6. PMID 3012008 DOI: 10.1200/Jco.1986.4.6.982 |
0.39 |
|
| 1986 |
Batist G, Katki AG, Ferrans VJ, Myers CE. The Role of Selenium Compounds in Cancer Therapy International Journal of Toxicology. 5: 87-93. DOI: 10.3109/10915818609140739 |
0.371 |
|
| 1985 |
Batist G, Klecker RW, Jayaram HN, Jenkins JF, Grygiel J, Ihde DC, Eddy JL, Fine RL, Kerr IG, Collins JM. Phase I and pharmacokinetic study of tiazofurin (TCAR, NSC 286193) administered by continuous infusion. Investigational New Drugs. 3: 349-55. PMID 4086242 DOI: 10.1007/Bf00170757 |
0.318 |
|
| 1985 |
Hamilton TC, Winker MA, Louie KG, Batist G, Behrens BC, Tsuruo T, Grotzinger KR, McKoy WM, Young RC, Ozols RF. Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion. Biochemical Pharmacology. 34: 2583-6. PMID 4040369 DOI: 10.1016/0006-2952(85)90551-9 |
0.343 |
|
| 1983 |
Batist G, Ihde DC, Zabell A, Lichter AS, Veach SR, Cohen MH, Carney DN, Bunn PA. Small-cell carcinoma of lung: Reinduction therapy after late relapse Annals of Internal Medicine. 98: 472-474. PMID 6301321 DOI: 10.7326/0003-4819-98-4-472 |
0.31 |
|
| Show low-probability matches. |